Following publication of the Preliminary Communication by Melissa Bersanelli, Letizia Gnetti, Cinzia Azzoni, Lorena Bottarelli, Nicola Sverzellati, Nicoletta Campanini, Elena Varotti, Michele Corrado, Raffaele Parziale, Elena Rapacchi, Giuseppe Caruso, Francesco Leonardi, Enrico Maria Silini & Sebastiano Buti, titled ‘Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab’, which appeared in the July 2018 issue of Immunotherapy (Immunotherapy 10[9], 743–752 [2018]; DOI: 10.2217/imt-2017-0160), it has been brought to our attention that Figure 4 was lacking the following abbreviations in the footnote: CB: Clinical benefit; LOH: Loss of heterozigosity; SD: Stable disease. In addition, Figure 1 was modified to read ‘MSI’ only in place of MSI and TMB high; and was added in.
The correct Figure 1 is shown below:
is shown below:
Table 2. Results of microsatellite instability and loss of heterozigosity analysis in the study population.
The authors and editors of Immunotherapy would like to sincerely apologise for any confusion or inconvenience this may have caused our readers.